Best Practices in the Diagnosis and Management of Homozygous Familial Hypercholesterolemia
This activity is supported by an educational grant from Regeneron.
Click Here to Manage Email Alerts
Overview
Release Date: December 6, 2022
Expiration Date: (12 months after release date): December 6, 2023
Program Description
Moderated by Dr. James Underberg, MD, MS, FACPM, FACP, FASH, FASPC, FNYAM, FNLA, this webcast activity provides a roundtable discussion with Dr. Seth S. Martin, MD, MHS, and Dr. Julie Brothers, MD and discusses strategies for the timely identification of patients with homozygous familial hypercholesterolemia (HoFH), the role of cascade screening in HoFH, current and emerging strategies for the treatment of HoFH, and treatment plans for both pediatrics and adults with HoFH.
Intended Audience
Cardiologists, lipidologists, endocrinologists, internists, primary care providers, infusion center nurses, pediatricians and other healthcare providers who treat patients with FH.
Commercial Supporter
This activity is supported by an educational grant from Regeneron.
Educational Objectives
Upon completion of the educational activity, participants should be able to:
- Implement strategies for the timely identification of patients with homozygous familial hypercholesterolemia (HoFH)
- Discuss the role of cascade screening in HoFH
- Describe current and emerging strategies for the treatment of HoFH
- Devise treatment plans for both pediatrics and adults with HoFH
Physician Continuing Education
In support of improving patient care, this activity has been planned and implemented by Horizon CME. Horizon CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Horizon CME designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.Conflicts of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, Horizon CME must ensure balance, independence, objectivity, and scientific rigor. Prior to an activity, all faculty, authors, editors, and planning committee members participating in a Horizon CME activity are required to disclose to attendees any relevant financial interest or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. Horizon CME has mitigated any conflicts of interest for this activity.
Disclosure of Unlabeled Use
Horizon CME requires that faculty participating in any continuing medical education (CME) to disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Faculty
Moderator:
James A. Underberg, MD, MS, FACP, FNLA,Clinical Assistant Professor of Medicine, NYU School of Medicine, NYU Center for Prevention of Cardiovascular Disease
Faculty:
Seth S. Martin, MD, MHS, Director of the Advanced Lipid Disorders Program and Digital Health Lab, Ciccarone Center for the Prevention of Cardiovascular Disease, Associate Professor of Medicine
Julie Brothers, MD, FAAP, Cardiologist, Director of the Lipid Heart Clinic at Children's Hospital of Philadelphia.
Faculty Disclosures
Julie Brothers, MD, FAAP, has served as on Speakers Bureau, Advisory Boards, as Consultant, and received research support from Regeneron Pharmaceuticals.
Seth S. Martin, MD, MHS, has served as on Speakers Bureau, Advisory Boards, as Consultant, and received research support from Novartis, Sanofi, Premier, Amgen, Novo, Nordisk, and AZ.
James A. Underberg, MD, MS, FACP, FNLA, has served as on Speakers Bureau, Advisory Boards, as Consultant, and received research support from Regeneron, Amgen, Esperion, Amryt Novartis, Merck, Pfizer, and Amgen.
Instructions to Recieve Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
1. Read the CME/CE information and faculty disclosures.
2. Participate in the online activity.
3. Complete the post-test.
4. Complete the evaluation form available. The last day to access the evaluation is November 15, 2023 at 11:59pm PST (Pacific Standard Time)
5. Certificates will be emailed to the participant
For CME questions please contact: info@horizon.com
To receive CME/CE credits, participants must complete the pre and post assessment questions and the program evaluation. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved within your Dashboard or Transcript, which you can access at any time. For information about the accreditation of this program, please contact: Brianna Bieleck, brianna.bielecki@horizoncme.com.
Dr. James Underberg:
Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology and President of the National Lipid Association. He is a Fellow of the National Lipid Association, a Fellow of the American College of Physicians, a Fellow of the NY Academy of Medicine, and Vice President of the American Board of Clinical Lipidology. He serves on the editorial board of the Journal of Clinical Lipidology and is a board member of the National Lipid Association, the Foundation of the National Lipid Association, The American Society of Preventive Cardiology, and the American Board of Clinical Lipidology. Dr. Underberg also serves on the scientific advisory board of the FH Foundation. The focus of Dr. Underberg’s clinical Interests include the clinical management of patients with lipids and lipoprotein disorders and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of Clinical Lipidology.
Dr. Seth S. Martin:
Dr. Martin is a core faculty member in the Ciccarone Center for the Prevention of Cardiovascular Disease and Director of the Advanced Lipid Disorders Center. Dr. Martin also serves as an Associate Faculty member in the Welch Center for Prevention, Epidemiology, and Clinical Research. He has a longstanding passion for preventive cardiology, in particular cardiovascular risk assessment, lipidology, and mobile health technology. Dr. Martin has published more than 170 articles in leading cardiology and medicine journals, as well as 15 book chapters. He serves as Associate Editor for the American College of Cardiology’s Dyslipidemia Clinical Community and as an Associate Editor for the Journal of Clinical Lipidology. Dr. Martin was selected as one of 125 faculty members, fellows, postdocs, staff and students who personify Johns Hopkins Medicine’s mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care, in celebration of the 125th Johns Hopkins Medicine anniversary.
Dr. Julie A. Brothers:
Dr. Brothers is the Medical Co-Director of the Preventive Cardiovascular Program and the Medical Director of the Lipid Heart Clinic at the Children’s Hospital of Philadelphia, a position she has held for over 15 years. She has served as Principal Investigator on several clinical trials in the pediatric dyslipidemia population and has published many manuscripts and book chapters on this topic. She is committed to promoting a heart healthy lifestyle in all children with lipid disorders.